Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer

BMC Cancer

Volumn 2, Issue , 2002, Pages

  Cao, Zhu Alexander ^a   Daniel, Dylan ^a   Hanahan, Douglas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CELL TRANSFER; CONTROLLED STUDY; IMMUNOMODULATION; IN VIVO STUDY; LYMPHOCYTE TRANSFER; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PANCREAS CANCER; SOLID TUMOR; SPLEEN CELL; STATISTICAL SIGNIFICANCE; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR VOLUME; ADOPTIVE TRANSFER; ANIMAL; C3H MOUSE; C57BL MOUSE; DISEASE MODEL; HUMAN; MALE; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; PANCREAS TUMOR; RADIATION EXPOSURE; SURVIVAL; TUMOR ASSOCIATED LEUKOCYTE;

ADOPTIVE TRANSFER; ANIMALS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0141446338     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-2-11     Document Type: Article

References (51)

1. Wang RF, Rosenberg SA: Human tumor antigens for cancer vaccine development. Immunol Rev 1999, 170:85-100
2. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA: Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995, 154:3961-3968
3. Rosenberg SA: Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997, 18:175-182
4. Dudley ME, Ngo LT, Westwood J, Wunderlich JR, Rosenberg SA: Tcell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. Cancer J 2000, 6:69-77
5. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM: Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of genemodified virus-specific T lymphocytes. Nat Med 1996, 2:551-555
6. Heslop HE, Rooney CM: Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev 1997, 157:217-222
7. Rooney CM, Smith CA, Heslop HE: Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity. Mol Med Today 1997, 3:24-30
8. Pardoll DM, Topalian SL: The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998, 10:588-594
9. Adler AJ, Marsh DW, Yochum GS, Guzzo JL, Nigam A, Nelson WG, Pardoll DM: CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J Exp Med 1998, 187:1555-1564
10. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll DM, Levitsky HI: Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A 1998, 95:1178-1183
11. Qin Z, Blankenstein T: T. CD4+ T cell - mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000, 12:677-686
12. Wick M, Dubey P, Koeppen H, Siegel CT, Fields PE, Chen L, Bluestone JA, Schreiber H: Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med 1997, 186:229-238
13. Speiser DE, Miranda R, Zakarian A, Bachmann MF, McKall-Faienza K, Odermatt B, Hanahan D, Zinkernagel RM, Ohashi PS: Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 1997, 186:645-653
14. Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA: A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci U S A 1990, 87:1486-1490
15. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J: Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996, 274:1363-1366
16. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR: Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat Med. 1996, 2:1361-1366
17. Jain RK: Delivery of molecular and cellular medicine to solid tumors. J Control Release 1998, 53:49-67
18. Wu NZ, Klitzman B, Dodge R, Dewhirst MW: Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Res 1992, 52:4265-4268
19. Onrust SV, Hartl PM, Rosen SD, Hanahan DD: Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. J Clin Invest 1996, 97:54-64
20. Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK: During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996, 2:992-997
21. Dellian M, Witwer BP, Salehi HA, Yuan F, Jain RK: Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. Am J Pathol 1996, 149:59-71
22. Ganss R, Hanahan D: Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res 1998, 58:4673-4681
23. Hanahan D: Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/ simian virus 40 oncogenes. Nature 1985, 315:115-122
24. Adams TE, Alpert S, Hanahan D: Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic beta cells. Nature 1987, 325:223-228
25. Jolicoeur C, Hanahan D, Smith KM: T-cell tolerance toward a transgenic beta-cell antigen and transcription of endogenous pancreatic genes in thymus. Proc Natl Acad Sci U S A 1994, 91:6707-6711
26. Smith KM, Olson DC, Hirose R, Hanahan D: Pancreatic gene expression in rare cells of thymic medulla: evidence for functional contribution to T cell tolerance. Int Immunol 1997, 9:1355-1365
27. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364
28. Forster I, Hirose R, Arbeit JM, Clausen BE, Hanahan D: Limited capacity for tolerization of CD4+ T cells specific for a pancreatic beta cell neo-antigen. Immunity 1995, 2:573-585
29. Geiger T, Soldevila G, Flavell RA: T cells are responsive to the simian virus 40 large tumor antigen transgenically expressed in pancreatic islets. J Immunol 1993, 151:7030-7037
30. Forster I, Lieberam I: Peripheral tolerance of CD4 T cells following local activation in adolescent mice. Eur J Immunol 1996, 26:3194-3202
31. Guerder S, Picarella DE, Linsley PS, Flavell RA: Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoimmunity in transgenic mice. Proc Natl Acad Sci U S A 1994, 91:5138-5142
32. Nishisaka N, Maini A, Kinoshita Y, Yasumoto R, Kishimoto T, Jones RF, Morse P, Hillman GG, Wang CY, Haas GP: Immunotherapy for lung metastases of murine renal cell carcinoma: synergy between radiation and cytokine-producing tumor vaccines. J Immunother 1999, 22:308-314
33. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999, 284:808-812
34. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T: B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998, 4:627-630
35. Antonia SJ, Extermann M, Flavell RA: Immunologic nonresponsiveness to tumors. Crit Rev Oncog 1998, 9:35-41
36. Seo N, Tokura Y: Downregulation of innate and acquired antitumor immunity by bystander gammadelta and alphabeta T lymphocytes with Th2 or Tr1 cytokine profiles. J Interferon Cytokine Res 1999, 19:555-561
37. Heier HE: The influence of therapeutic irradiation of blood and peripheral lymph lymphocytes. Lymphology 1978, 11:238-242
38. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 1994, 12:991-1045
39. Hirao M, Onai N, Hiroishi K, Watkins SC, Matsushima K, Robbins PD, Lotze MT, Tahara H: CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res 2000, 60:2209-2217
40. Restifo NP: Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Curr Opin Immunol 2000, 12:597-603
41. Shi Y, Zheng W, Rock KL: Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc Natl Acad Sci U S A 2000, 97:14590-14595
42. Scholzen T, Hartmeyer M, Fastrich M, Brzoska T, Becher E, Schwarz T, Luger TA: Ultraviolet light and interleukin-10 modulate expression of cytokines by transformed human dermal microvascular endothelial cells (HMEC-1). J Invest Dermatol 1998, 111:50-56
43. Van Der Meeren A, Squiban C, Gourmelon P, Lafont H, Gaugler MH: Differential regulation by IL-4 and IL-10 of radiation-induced IL-6 and IL-8 production and ICAM-1 expression by human endothelial cells. Cytokine 1999, 11:831-838
44. Huber MA, Kraut N, Addicks T, Peter RU: Cell-type-dependent induction of eotaxin and CCR3 by ionizing radiation. Biochem Biophys Res Commun 2000, 269:546-552
45. Sojka DK, Donepudi M, Bluestone JA, Mokyr MB: Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. J Immunol 2000, 164:6230-6236
46. Younes E, Haas GP, Dezso B, Ali E, Maughan RL, Kukuruga MA, Montecillo E, Pontes JE, Hillman GG: Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma. Cell Immunol 1995, 165:243-251
47. Santin AD, Hiserodt JC, Fruehauf J, DiSaia PJ, Pecorelli S, Granger GA: Effects of irradiation on the expression of surface antigens in human ovarian cancer. Gynecol Oncol 1996, 60:468-474
48. Huang AY, Bruce AT, Pardoll DM, Levitsky HI: Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 1996, 183:769-776
49. Cayeux S, Richter G, Noffz G, Dorken B, Blankenstein T: Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. J Immunol 1997, 158:2834-2841
50. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998, 392:245-252
51. Limmer A, Ohl J, Kurts C, Ljunggren HG, Reiss Y, Groettrup M, Momburg F, Arnold B, Knolle PA: Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med 2000, 6:1348-1354